Introduction: A substantial survival benefit with chemohormonal therapy has been proven by the CHAARTED and STAMPEDE studies, and this clinical approach has emerged as the standard of care for patients with metastatic hormone-naïve prostate cancer (mHSPC). However, because its clinical efficacy and tolerability in Asian patients remains uncertain, this study aims to evaluate preliminary results of its use in Hong Kong.
INTRODUCTION
Prostate cancer is the third most commonly diagnosed cancer among males in Hong Kong. 1 The incidence rate reflects the largest increase recorded among the common male cancers over the past two decades.
According to the latest figures released by the Hong Kong Cancer
Registry, there were more than 1709 newly diagnosed cases, which accounted for 11.3% of all new male cancer cases, in 2014. 2 The age-standardized rate of prostate cancer incidence also increased
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. 1 Despite the advancement of surgical techniques together with the increasing availability of different systemic therapies, trends in prostate cancer prevalence, incidence and survival suggest that the number of men with prostate cancer who require treatment will augment in the coming years. 3, 4 Therefore, new and promising treatment options are needed to effectively control the prostate cancer disease burden with minimal impact to the patients' quality of life.
It has been well documented that prostate cancer can be influenced by androgenic activity in the body. [5] [6] [7] In 1940, regression of metastatic prostate cancer was proven to be achievable by castration, either surgically or chemically. 6 Since then, androgen deprivation therapy (ADT) has become the mainstay of first-line treatment for metastatic prostate cancer. 8 Although the majority of the patients (>90%) initially respond to ADT, resistance occurs in most patients with a median survival of approximately 3 years, with patients ultimately progressing to castration resistance. 9 Docetaxel in combination with prednisolone has been demonstrated to improve survival and quality of life in patients with metastatic castrationresistant prostate cancer (mCRPC). 10, 11 By demonstrating an extended survival benefit of 2.5 months, these results have changed the standard of care for mCRPC from mitoxantrone/prednisone to docetaxel/prednisone. 10 However, the ideal regimen remains controversial, with continuing debates which include the optimal number of treatment cycles, and whether a fixed number of cycles should be given until the best response or intermittent treatment to avoid excessive toxicity. 12 No standard second-line treatments emerged until 2010, in which other therapeutic options including sipuleucel-T, cabazitaxel, abiraterone acetate, enzalutamide and radium-223 began to show decent survival benefits. 13 In terms of clinical outcomes among the therapeutic interventions in the mCRPC setting, survival benefits are not robust, that is up to 5 months as demonstrated in most clinical trials. However, the recent publication of two randomized phase 3 trials that evaluated the combined use of ADT with docetaxel in men with metastatic hormonesensitive prostate cancer yielded remarkable overall survival benefits of 13.6 months (CHAARTED) 14 and 10 months (STAMPEDE) 15 compared with ADT alone. 14, 15 The clinical benefit at this early analysis was more pronounced among patients with a higher burden of disease. The results demonstrated superiority in overall survival across all previous histologic mPC trials. 16 Based on consistency of the data and the benefits provided, docetaxel in addition to ADT is recommended as the standard of care for men with newly diagnosed hormone-naïve prostate cancer (mHSPC) in many international guidelines. [17] [18] [19] Currently, there have been no studies conducted in an Asian population for the concurrent use of ADT and docetaxel in the hormone-naïve setting. We sought to evaluate the efficacy and toxicities of this combinational regimen in mHSPC patients with high-volume disease from all six public oncology centers in Hong Kong.
METHODS

Population of interest
Ethics statement
The study was approved by the institutional review board of the CRE-2017.396). Permission to access the medical records through the inter-hospital computer network was granted by the aforementioned review board. The principles of the Helsinki Declaration were applied and followed. Permission to access the medical records was granted by the same board. Informed consent was obtained from patients before starting the treatment.
Study population and treatment
The 
Data collection and outcome measures
Statistical analysis
Survival analyses were conducted using a Kaplan- 
RESULTS
Patient demographics
Thirty-two patients were included for the assessment during the study period and their baseline characteristics are shown in 
Primary endpoint -Time to CRPC
After a median follow-up of 11.4 months, the median time to castration-resistance was 19.5 months (Figure 1 ), which is comparable to the result found in the CHAARTED study (i.e. 20.2 months). 14 
Secondary endpoints -prostate-specific antigen (PSA) response, time to PSA nadir and treatment-related complications
The median time to PSA nadir was 7 months. The PSA response (>50% drop in PSA level from baseline) was achieved in all patients, and the median maximal PSA response was 99.6%. Table 3 shows the treatment-related complications among the mHSPC patients who received the chemohormonal regimen. The rates of grade 3 or 4 febrile neutropenia, neutropenia and anemia were 12.5%, 40.6% and 3.1%, respectively, while no cases of grade 3 or 4 thrombocytopenia, neuropathy, fatigue, diarrhea or stomatitis were reported.
DISCUSSION
The current study reported the use of ADT and docetaxel in the Asian population in the hormone-naive setting. The current cohort demonstrates that chemohormonal therapy has good efficacy in Chinese mHSPC patients, while chemotherapy-related hematologic toxicities were observed in Chinese patients which suggests the need to have proper patient selection.
ADT has been recognized as the standard treatment for mHSPC, Chinese patients in the current study compared with Western populations (Table 4) . While there were reports of neuropathy, fatigue, diarrhea and stomatitis among the Caucasian patients in the CHAARTED and STAMPEDE studies, there were no reports of these toxicities in the current study. The incidence rates of the various hematologic toxicities also resemble our previous study cohort, 22 demonstrating that the toxicity profile is consistent among Chinese patients. Pre-emptive use of granulocyte-colony stimulating factor (GCSF) to alleviate hematologic toxicity is suggested in these patients when docetaxel combination therapy is adopted. According to local clinical experience, docetaxel had been given to elderly patients of up to 80 years of age.
TA B L E 4 Comparison of grade 3 or above toxicities in related studies
Therefore, age may not necessarily be a critical factor in deciding whether to initiate the chemohormonal treatment. Instead, other factors, such as patient's general health conditions and presence of comorbidities, are to be considered.
We observed differences in clinical practice, selection bias and data collection between hospitals, which is typical of real-world practice.
The inconsistent treatment protocols and policies between hospitals during data collection adds a further drawback to this study; therefore, a consensus is necessary to draw consistent treatment guidelines. Further follow up is needed to accurately define progression-free survival and overall survival.
CONCLUSION
In conclusion, based on the current evidence and treatment guidelines worldwide, early combination of chemo plus ADT should be the standard of care in patients with metastatic castration-naïve prostate cancer. Our current cohort has illustrated that chemohormonal therapy is efficacious in Chinese mHSPC patients, while chemotherapyrelated hematologic toxicities in Chinese patients are more frequent and hence proper patient selection with pre-emptive use of GCSF is recommended. Further follow-up would be necessary to validate and monitor the survival impact on mHSPC patients.
